Early cancer detection startup GRAIL closes on $900 million in Series B funding

 Life sciences startups need a whole lot more cash than most and that’s certainly true for GRAIL, a cancer detection startup trying to figure out a way to find the “emperor of all maladies” much earlier through blood testing technology. The startup, which spun out of genomics company Illumina announced it has closed a whopping $900 million in Series B funding this morning.… Read More

http://ift.tt/2cmWvTj Early cancer detection startup GRAIL closes on $900 million in Series B funding http://ift.tt/2lrDq1R